nodes	percent_of_prediction	percent_of_DWPC	metapath
Sitaxentan—CYP2C19—Sorafenib—thyroid cancer	0.074	0.293	CbGbCtD
Sitaxentan—CYP2C9—Sorafenib—thyroid cancer	0.0615	0.244	CbGbCtD
Sitaxentan—CYP3A4—Vandetanib—thyroid cancer	0.0594	0.235	CbGbCtD
Sitaxentan—CYP3A4—Sorafenib—thyroid cancer	0.0358	0.142	CbGbCtD
Sitaxentan—CYP3A4—Doxorubicin—thyroid cancer	0.0217	0.086	CbGbCtD
Sitaxentan—EDNRB—Prostaglandin Synthesis and Regulation—HPGD—thyroid cancer	0.0159	0.136	CbGpPWpGaD
Sitaxentan—EDNRA—Prostaglandin Synthesis and Regulation—HPGD—thyroid cancer	0.0114	0.0977	CbGpPWpGaD
Sitaxentan—EDNRB—Endothelin Pathways—CALCA—thyroid cancer	0.00634	0.0544	CbGpPWpGaD
Sitaxentan—EDNRA—Endothelin Pathways—CALCA—thyroid cancer	0.00454	0.0389	CbGpPWpGaD
Sitaxentan—EDNRB—Peptide GPCRs—TSHR—thyroid cancer	0.00444	0.0381	CbGpPWpGaD
Sitaxentan—EDNRA—Peptide GPCRs—TSHR—thyroid cancer	0.00318	0.0272	CbGpPWpGaD
Sitaxentan—EDNRA—EGFR-dependent Endothelin signaling events—HRAS—thyroid cancer	0.00305	0.0261	CbGpPWpGaD
Sitaxentan—EDNRB—Prostaglandin Synthesis and Regulation—PTGS2—thyroid cancer	0.00286	0.0245	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—CALCB—thyroid cancer	0.0023	0.0198	CbGpPWpGaD
Sitaxentan—EDNRA—Prostaglandin Synthesis and Regulation—PTGS2—thyroid cancer	0.00204	0.0175	CbGpPWpGaD
Sitaxentan—CYP2C19—Arachidonic acid metabolism—HPGD—thyroid cancer	0.00179	0.0153	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—CALCB—thyroid cancer	0.00165	0.0141	CbGpPWpGaD
Sitaxentan—CYP2C9—Arachidonic acid metabolism—HPGD—thyroid cancer	0.00163	0.014	CbGpPWpGaD
Sitaxentan—EDNRB—Peptide ligand-binding receptors—SST—thyroid cancer	0.00162	0.0139	CbGpPWpGaD
Sitaxentan—CYP3A4—Liver X Receptor Pathway—RXRA—thyroid cancer	0.00141	0.0121	CbGpPWpGaD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—TSHR—thyroid cancer	0.0014	0.012	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—CALCB—thyroid cancer	0.0013	0.0112	CbGpPWpGaD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—CDK1—thyroid cancer	0.00128	0.011	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—CALCB—thyroid cancer	0.00118	0.0101	CbGpPWpGaD
Sitaxentan—EDNRA—Peptide ligand-binding receptors—SST—thyroid cancer	0.00116	0.00996	CbGpPWpGaD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—SST—thyroid cancer	0.00109	0.00934	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—TSHR—thyroid cancer	0.00107	0.00914	CbGpPWpGaD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—TSHR—thyroid cancer	0.001	0.00859	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—CALCB—thyroid cancer	0.000932	0.00799	CbGpPWpGaD
Sitaxentan—CYP2C19—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000922	0.00791	CbGpPWpGaD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—CDK1—thyroid cancer	0.000917	0.00786	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—PTCH1—thyroid cancer	0.000907	0.00777	CbGpPWpGaD
Sitaxentan—EDNRB—Endothelins—HRAS—thyroid cancer	0.000898	0.0077	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—CALCB—thyroid cancer	0.000846	0.00725	CbGpPWpGaD
Sitaxentan—CYP3A4—Farnesoid X Receptor  Pathway—RXRA—thyroid cancer	0.000841	0.00721	CbGpPWpGaD
Sitaxentan—CYP2C9—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000841	0.00721	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—SST—thyroid cancer	0.000829	0.00711	CbGpPWpGaD
Sitaxentan—CYP2C19—Metapathway biotransformation—CHST14—thyroid cancer	0.000813	0.00697	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—CALCA—thyroid cancer	0.000798	0.00685	CbGpPWpGaD
Sitaxentan—EDNRB—Endothelins—AKT1—thyroid cancer	0.000793	0.0068	CbGpPWpGaD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—SST—thyroid cancer	0.00078	0.00668	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—TSHR—thyroid cancer	0.000763	0.00654	CbGpPWpGaD
Sitaxentan—CYP2C9—Metapathway biotransformation—CHST14—thyroid cancer	0.000742	0.00636	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CALCB—thyroid cancer	0.000698	0.00599	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—TRIM33—thyroid cancer	0.000662	0.00568	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—PTCH1—thyroid cancer	0.000649	0.00556	CbGpPWpGaD
Sitaxentan—EDNRA—Endothelins—HRAS—thyroid cancer	0.000643	0.00551	CbGpPWpGaD
Sitaxentan—Dizziness—Vandetanib—thyroid cancer	0.000606	0.000961	CcSEcCtD
Sitaxentan—Thrombocytopenia—Sorafenib—thyroid cancer	0.000606	0.00096	CcSEcCtD
Sitaxentan—Vaginal infection—Epirubicin—thyroid cancer	0.000605	0.000958	CcSEcCtD
Sitaxentan—Blood uric acid increased—Doxorubicin—thyroid cancer	0.000604	0.000957	CcSEcCtD
Sitaxentan—EDNRB—GPCR downstream signaling—TSHR—thyroid cancer	0.000603	0.00517	CbGpPWpGaD
Sitaxentan—Skin disorder—Sorafenib—thyroid cancer	0.000601	0.000952	CcSEcCtD
Sitaxentan—Musculoskeletal pain—Doxorubicin—thyroid cancer	0.0006	0.000951	CcSEcCtD
Sitaxentan—EDNRA—GPCR ligand binding—SST—thyroid cancer	0.000594	0.00509	CbGpPWpGaD
Sitaxentan—Pulmonary embolism—Doxorubicin—thyroid cancer	0.000593	0.000939	CcSEcCtD
Sitaxentan—Hiccups—Doxorubicin—thyroid cancer	0.000593	0.000939	CcSEcCtD
Sitaxentan—Ventricular tachycardia—Doxorubicin—thyroid cancer	0.000593	0.000939	CcSEcCtD
Sitaxentan—Dry eye—Epirubicin—thyroid cancer	0.000592	0.000938	CcSEcCtD
Sitaxentan—Anorexia—Sorafenib—thyroid cancer	0.00059	0.000934	CcSEcCtD
Sitaxentan—Dermatitis contact—Doxorubicin—thyroid cancer	0.000586	0.000928	CcSEcCtD
Sitaxentan—Vomiting—Vandetanib—thyroid cancer	0.000583	0.000924	CcSEcCtD
Sitaxentan—Hyperkalaemia—Doxorubicin—thyroid cancer	0.000582	0.000923	CcSEcCtD
Sitaxentan—Eructation—Doxorubicin—thyroid cancer	0.000582	0.000923	CcSEcCtD
Sitaxentan—Neoplasm—Epirubicin—thyroid cancer	0.000579	0.000918	CcSEcCtD
Sitaxentan—Rash—Vandetanib—thyroid cancer	0.000578	0.000916	CcSEcCtD
Sitaxentan—Dermatitis—Vandetanib—thyroid cancer	0.000578	0.000915	CcSEcCtD
Sitaxentan—Headache—Vandetanib—thyroid cancer	0.000574	0.00091	CcSEcCtD
Sitaxentan—EDNRA—GPCR ligand binding—CALCA—thyroid cancer	0.000571	0.0049	CbGpPWpGaD
Sitaxentan—Colitis—Doxorubicin—thyroid cancer	0.000569	0.000902	CcSEcCtD
Sitaxentan—EDNRA—Endothelins—AKT1—thyroid cancer	0.000567	0.00486	CbGpPWpGaD
Sitaxentan—Skin exfoliation—Doxorubicin—thyroid cancer	0.000566	0.000897	CcSEcCtD
Sitaxentan—Candida infection—Doxorubicin—thyroid cancer	0.000566	0.000897	CcSEcCtD
Sitaxentan—Fluid retention—Doxorubicin—thyroid cancer	0.000563	0.000892	CcSEcCtD
Sitaxentan—Vaginal infection—Doxorubicin—thyroid cancer	0.00056	0.000887	CcSEcCtD
Sitaxentan—CYP2C19—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000558	0.00478	CbGpPWpGaD
Sitaxentan—Mental disability—Epirubicin—thyroid cancer	0.000556	0.000881	CcSEcCtD
Sitaxentan—CYP3A4—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000555	0.00475	CbGpPWpGaD
Sitaxentan—Dry eye—Doxorubicin—thyroid cancer	0.000547	0.000868	CcSEcCtD
Sitaxentan—EDNRB—Signaling by GPCR—TSHR—thyroid cancer	0.000547	0.00469	CbGpPWpGaD
Sitaxentan—Nausea—Vandetanib—thyroid cancer	0.000545	0.000863	CcSEcCtD
Sitaxentan—Dyspepsia—Sorafenib—thyroid cancer	0.000544	0.000863	CcSEcCtD
Sitaxentan—EDNRB—Signaling by GPCR—PRKAR1A—thyroid cancer	0.000538	0.00462	CbGpPWpGaD
Sitaxentan—Decreased appetite—Sorafenib—thyroid cancer	0.000538	0.000852	CcSEcCtD
Sitaxentan—Neoplasm—Doxorubicin—thyroid cancer	0.000536	0.000849	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.000534	0.000846	CcSEcCtD
Sitaxentan—Fatigue—Sorafenib—thyroid cancer	0.000533	0.000845	CcSEcCtD
Sitaxentan—Constipation—Sorafenib—thyroid cancer	0.000529	0.000838	CcSEcCtD
Sitaxentan—Pain—Sorafenib—thyroid cancer	0.000529	0.000838	CcSEcCtD
Sitaxentan—Hepatic failure—Epirubicin—thyroid cancer	0.000517	0.00082	CcSEcCtD
Sitaxentan—Mental disability—Doxorubicin—thyroid cancer	0.000514	0.000815	CcSEcCtD
Sitaxentan—Cardiac failure congestive—Epirubicin—thyroid cancer	0.000513	0.000813	CcSEcCtD
Sitaxentan—CYP2C9—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000508	0.00436	CbGpPWpGaD
Sitaxentan—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000506	0.00434	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CALCB—thyroid cancer	0.0005	0.00429	CbGpPWpGaD
Sitaxentan—Increased appetite—Epirubicin—thyroid cancer	0.000495	0.000784	CcSEcCtD
Sitaxentan—Menopausal symptoms—Epirubicin—thyroid cancer	0.000493	0.000781	CcSEcCtD
Sitaxentan—Urticaria—Sorafenib—thyroid cancer	0.000491	0.000779	CcSEcCtD
Sitaxentan—CYP3A4—Metapathway biotransformation—CHST14—thyroid cancer	0.000489	0.00419	CbGpPWpGaD
Sitaxentan—Body temperature increased—Sorafenib—thyroid cancer	0.000489	0.000775	CcSEcCtD
Sitaxentan—Renal impairment—Epirubicin—thyroid cancer	0.000489	0.000774	CcSEcCtD
Sitaxentan—Hepatic failure—Doxorubicin—thyroid cancer	0.000479	0.000759	CcSEcCtD
Sitaxentan—Hypoglycaemia—Epirubicin—thyroid cancer	0.000476	0.000755	CcSEcCtD
Sitaxentan—Cardiac failure—Epirubicin—thyroid cancer	0.000476	0.000755	CcSEcCtD
Sitaxentan—Cardiac failure congestive—Doxorubicin—thyroid cancer	0.000474	0.000752	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—TRIM33—thyroid cancer	0.000474	0.00406	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—SST—thyroid cancer	0.000469	0.00402	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—PTCH1—thyroid cancer	0.000465	0.00399	CbGpPWpGaD
Sitaxentan—Gastrointestinal haemorrhage—Epirubicin—thyroid cancer	0.000465	0.000737	CcSEcCtD
Sitaxentan—Osteoarthritis—Epirubicin—thyroid cancer	0.000465	0.000737	CcSEcCtD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—thyroid cancer	0.00046	0.00394	CbGpPWpGaD
Sitaxentan—Increased appetite—Doxorubicin—thyroid cancer	0.000458	0.000726	CcSEcCtD
Sitaxentan—Migraine—Epirubicin—thyroid cancer	0.000458	0.000725	CcSEcCtD
Sitaxentan—Menopausal symptoms—Doxorubicin—thyroid cancer	0.000456	0.000723	CcSEcCtD
Sitaxentan—Hypersensitivity—Sorafenib—thyroid cancer	0.000456	0.000722	CcSEcCtD
Sitaxentan—Renal impairment—Doxorubicin—thyroid cancer	0.000452	0.000716	CcSEcCtD
Sitaxentan—CYP2C19—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000452	0.00388	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—CALCA—thyroid cancer	0.000451	0.00387	CbGpPWpGaD
Sitaxentan—Asthenia—Sorafenib—thyroid cancer	0.000444	0.000703	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—TCF7L1—thyroid cancer	0.000442	0.00379	CbGpPWpGaD
Sitaxentan—Cardiac failure—Doxorubicin—thyroid cancer	0.000441	0.000699	CcSEcCtD
Sitaxentan—Hypoglycaemia—Doxorubicin—thyroid cancer	0.000441	0.000699	CcSEcCtD
Sitaxentan—Ataxia—Epirubicin—thyroid cancer	0.000437	0.000693	CcSEcCtD
Sitaxentan—Blood creatinine increased—Epirubicin—thyroid cancer	0.000436	0.00069	CcSEcCtD
Sitaxentan—Dehydration—Epirubicin—thyroid cancer	0.000432	0.000685	CcSEcCtD
Sitaxentan—EDNRA—GPCR downstream signaling—TSHR—thyroid cancer	0.000431	0.0037	CbGpPWpGaD
Sitaxentan—Osteoarthritis—Doxorubicin—thyroid cancer	0.00043	0.000682	CcSEcCtD
Sitaxentan—Gastrointestinal haemorrhage—Doxorubicin—thyroid cancer	0.00043	0.000682	CcSEcCtD
Sitaxentan—Liver function test abnormal—Epirubicin—thyroid cancer	0.000429	0.00068	CcSEcCtD
Sitaxentan—Dry skin—Epirubicin—thyroid cancer	0.000426	0.000675	CcSEcCtD
Sitaxentan—EDNRB—Signaling by GPCR—SST—thyroid cancer	0.000426	0.00365	CbGpPWpGaD
Sitaxentan—Abdominal pain upper—Epirubicin—thyroid cancer	0.000425	0.000673	CcSEcCtD
Sitaxentan—Orthostatic hypotension—Epirubicin—thyroid cancer	0.000425	0.000673	CcSEcCtD
Sitaxentan—Migraine—Doxorubicin—thyroid cancer	0.000424	0.000671	CcSEcCtD
Sitaxentan—Diarrhoea—Sorafenib—thyroid cancer	0.000423	0.000671	CcSEcCtD
Sitaxentan—Breast disorder—Epirubicin—thyroid cancer	0.00042	0.000666	CcSEcCtD
Sitaxentan—Aspartate aminotransferase increased—Epirubicin—thyroid cancer	0.000419	0.000664	CcSEcCtD
Sitaxentan—CYP2C9—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000412	0.00353	CbGpPWpGaD
Sitaxentan—Muscular weakness—Epirubicin—thyroid cancer	0.00041	0.00065	CcSEcCtD
Sitaxentan—Alanine aminotransferase increased—Epirubicin—thyroid cancer	0.00041	0.00065	CcSEcCtD
Sitaxentan—EDNRB—Signaling by GPCR—CALCA—thyroid cancer	0.00041	0.00351	CbGpPWpGaD
Sitaxentan—Dizziness—Sorafenib—thyroid cancer	0.000409	0.000648	CcSEcCtD
Sitaxentan—Ataxia—Doxorubicin—thyroid cancer	0.000405	0.000641	CcSEcCtD
Sitaxentan—Blood creatinine increased—Doxorubicin—thyroid cancer	0.000403	0.000639	CcSEcCtD
Sitaxentan—Asthma—Epirubicin—thyroid cancer	0.000402	0.000637	CcSEcCtD
Sitaxentan—Dehydration—Doxorubicin—thyroid cancer	0.0004	0.000634	CcSEcCtD
Sitaxentan—Eosinophilia—Epirubicin—thyroid cancer	0.000398	0.000631	CcSEcCtD
Sitaxentan—Liver function test abnormal—Doxorubicin—thyroid cancer	0.000397	0.00063	CcSEcCtD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—thyroid cancer	0.000396	0.00339	CbGpPWpGaD
Sitaxentan—Dry skin—Doxorubicin—thyroid cancer	0.000394	0.000625	CcSEcCtD
Sitaxentan—Vomiting—Sorafenib—thyroid cancer	0.000393	0.000623	CcSEcCtD
Sitaxentan—Orthostatic hypotension—Doxorubicin—thyroid cancer	0.000393	0.000623	CcSEcCtD
Sitaxentan—Abdominal pain upper—Doxorubicin—thyroid cancer	0.000393	0.000623	CcSEcCtD
Sitaxentan—EDNRA—Signaling by GPCR—TSHR—thyroid cancer	0.000392	0.00336	CbGpPWpGaD
Sitaxentan—Angina pectoris—Epirubicin—thyroid cancer	0.000392	0.00062	CcSEcCtD
Sitaxentan—Rash—Sorafenib—thyroid cancer	0.00039	0.000618	CcSEcCtD
Sitaxentan—Dermatitis—Sorafenib—thyroid cancer	0.00039	0.000617	CcSEcCtD
Sitaxentan—Breast disorder—Doxorubicin—thyroid cancer	0.000389	0.000616	CcSEcCtD
Sitaxentan—Aspartate aminotransferase increased—Doxorubicin—thyroid cancer	0.000387	0.000614	CcSEcCtD
Sitaxentan—Headache—Sorafenib—thyroid cancer	0.000387	0.000614	CcSEcCtD
Sitaxentan—Bronchitis—Epirubicin—thyroid cancer	0.000387	0.000613	CcSEcCtD
Sitaxentan—EDNRA—Signaling by GPCR—PRKAR1A—thyroid cancer	0.000385	0.0033	CbGpPWpGaD
Sitaxentan—Pancytopenia—Epirubicin—thyroid cancer	0.000382	0.000605	CcSEcCtD
Sitaxentan—Muscular weakness—Doxorubicin—thyroid cancer	0.000379	0.000601	CcSEcCtD
Sitaxentan—Alanine aminotransferase increased—Doxorubicin—thyroid cancer	0.000379	0.000601	CcSEcCtD
Sitaxentan—Dysuria—Epirubicin—thyroid cancer	0.000376	0.000596	CcSEcCtD
Sitaxentan—Asthma—Doxorubicin—thyroid cancer	0.000372	0.000589	CcSEcCtD
Sitaxentan—Pollakiuria—Epirubicin—thyroid cancer	0.000371	0.000588	CcSEcCtD
Sitaxentan—EDNRB—Signaling by GPCR—CDK1—thyroid cancer	0.000371	0.00318	CbGpPWpGaD
Sitaxentan—Eosinophilia—Doxorubicin—thyroid cancer	0.000368	0.000583	CcSEcCtD
Sitaxentan—Nausea—Sorafenib—thyroid cancer	0.000367	0.000582	CcSEcCtD
Sitaxentan—Photosensitivity reaction—Epirubicin—thyroid cancer	0.000367	0.000581	CcSEcCtD
Sitaxentan—Weight decreased—Epirubicin—thyroid cancer	0.000364	0.000576	CcSEcCtD
Sitaxentan—Hyperglycaemia—Epirubicin—thyroid cancer	0.000363	0.000575	CcSEcCtD
Sitaxentan—Angina pectoris—Doxorubicin—thyroid cancer	0.000362	0.000574	CcSEcCtD
Sitaxentan—Infestation NOS—Epirubicin—thyroid cancer	0.000358	0.000568	CcSEcCtD
Sitaxentan—Infestation—Epirubicin—thyroid cancer	0.000358	0.000568	CcSEcCtD
Sitaxentan—Bronchitis—Doxorubicin—thyroid cancer	0.000358	0.000567	CcSEcCtD
Sitaxentan—Pancytopenia—Doxorubicin—thyroid cancer	0.000353	0.00056	CcSEcCtD
Sitaxentan—Renal failure—Epirubicin—thyroid cancer	0.000352	0.000558	CcSEcCtD
Sitaxentan—Stomatitis—Epirubicin—thyroid cancer	0.000349	0.000554	CcSEcCtD
Sitaxentan—Jaundice—Epirubicin—thyroid cancer	0.000349	0.000554	CcSEcCtD
Sitaxentan—Conjunctivitis—Epirubicin—thyroid cancer	0.000348	0.000552	CcSEcCtD
Sitaxentan—Dysuria—Doxorubicin—thyroid cancer	0.000348	0.000551	CcSEcCtD
Sitaxentan—Pollakiuria—Doxorubicin—thyroid cancer	0.000344	0.000544	CcSEcCtD
Sitaxentan—Haematuria—Epirubicin—thyroid cancer	0.000342	0.000541	CcSEcCtD
Sitaxentan—Photosensitivity reaction—Doxorubicin—thyroid cancer	0.000339	0.000538	CcSEcCtD
Sitaxentan—Hepatobiliary disease—Epirubicin—thyroid cancer	0.000339	0.000537	CcSEcCtD
Sitaxentan—Epistaxis—Epirubicin—thyroid cancer	0.000338	0.000536	CcSEcCtD
Sitaxentan—Weight decreased—Doxorubicin—thyroid cancer	0.000336	0.000533	CcSEcCtD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—thyroid cancer	0.000336	0.00288	CbGpPWpGaD
Sitaxentan—Sinusitis—Epirubicin—thyroid cancer	0.000336	0.000533	CcSEcCtD
Sitaxentan—Hyperglycaemia—Doxorubicin—thyroid cancer	0.000335	0.000532	CcSEcCtD
Sitaxentan—EDNRA—GPCR downstream signaling—SST—thyroid cancer	0.000335	0.00288	CbGpPWpGaD
Sitaxentan—CYP3A4—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000335	0.00288	CbGpPWpGaD
Sitaxentan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000334	0.00286	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—PTCH1—thyroid cancer	0.000333	0.00286	CbGpPWpGaD
Sitaxentan—Infestation NOS—Doxorubicin—thyroid cancer	0.000332	0.000525	CcSEcCtD
Sitaxentan—Infestation—Doxorubicin—thyroid cancer	0.000332	0.000525	CcSEcCtD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—thyroid cancer	0.000329	0.00282	CbGpPWpGaD
Sitaxentan—Bradycardia—Epirubicin—thyroid cancer	0.000328	0.000519	CcSEcCtD
Sitaxentan—Renal failure—Doxorubicin—thyroid cancer	0.000326	0.000517	CcSEcCtD
Sitaxentan—Haemoglobin—Epirubicin—thyroid cancer	0.000323	0.000512	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—TSHR—thyroid cancer	0.000323	0.00277	CbGpPWpGaD
Sitaxentan—Stomatitis—Doxorubicin—thyroid cancer	0.000323	0.000512	CcSEcCtD
Sitaxentan—Jaundice—Doxorubicin—thyroid cancer	0.000323	0.000512	CcSEcCtD
Sitaxentan—EDNRA—GPCR downstream signaling—CALCA—thyroid cancer	0.000323	0.00277	CbGpPWpGaD
Sitaxentan—Rhinitis—Epirubicin—thyroid cancer	0.000323	0.000511	CcSEcCtD
Sitaxentan—Conjunctivitis—Doxorubicin—thyroid cancer	0.000322	0.000511	CcSEcCtD
Sitaxentan—Haemorrhage—Epirubicin—thyroid cancer	0.000322	0.00051	CcSEcCtD
Sitaxentan—Hepatitis—Epirubicin—thyroid cancer	0.000322	0.00051	CcSEcCtD
Sitaxentan—CYP2C19—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.00032	0.00275	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—PRKAR1A—thyroid cancer	0.000318	0.00273	CbGpPWpGaD
Sitaxentan—Urinary tract disorder—Epirubicin—thyroid cancer	0.000318	0.000503	CcSEcCtD
Sitaxentan—Oedema peripheral—Epirubicin—thyroid cancer	0.000317	0.000502	CcSEcCtD
Sitaxentan—Haematuria—Doxorubicin—thyroid cancer	0.000316	0.000501	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—TCF7L1—thyroid cancer	0.000316	0.00271	CbGpPWpGaD
Sitaxentan—Urethral disorder—Epirubicin—thyroid cancer	0.000315	0.0005	CcSEcCtD
Sitaxentan—Hepatobiliary disease—Doxorubicin—thyroid cancer	0.000314	0.000497	CcSEcCtD
Sitaxentan—Epistaxis—Doxorubicin—thyroid cancer	0.000313	0.000496	CcSEcCtD
Sitaxentan—Sinusitis—Doxorubicin—thyroid cancer	0.000311	0.000493	CcSEcCtD
Sitaxentan—Visual impairment—Epirubicin—thyroid cancer	0.00031	0.000491	CcSEcCtD
Sitaxentan—EDNRA—Signaling by GPCR—SST—thyroid cancer	0.000305	0.00261	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—MEN1—thyroid cancer	0.000304	0.00261	CbGpPWpGaD
Sitaxentan—Bradycardia—Doxorubicin—thyroid cancer	0.000303	0.00048	CcSEcCtD
Sitaxentan—Eye disorder—Epirubicin—thyroid cancer	0.000301	0.000476	CcSEcCtD
Sitaxentan—Tinnitus—Epirubicin—thyroid cancer	0.0003	0.000475	CcSEcCtD
Sitaxentan—Haemoglobin—Doxorubicin—thyroid cancer	0.000299	0.000474	CcSEcCtD
Sitaxentan—Cardiac disorder—Epirubicin—thyroid cancer	0.000299	0.000473	CcSEcCtD
Sitaxentan—Flushing—Epirubicin—thyroid cancer	0.000299	0.000473	CcSEcCtD
Sitaxentan—Rhinitis—Doxorubicin—thyroid cancer	0.000298	0.000473	CcSEcCtD
Sitaxentan—Haemorrhage—Doxorubicin—thyroid cancer	0.000298	0.000472	CcSEcCtD
Sitaxentan—Hepatitis—Doxorubicin—thyroid cancer	0.000298	0.000472	CcSEcCtD
Sitaxentan—Urinary tract disorder—Doxorubicin—thyroid cancer	0.000294	0.000466	CcSEcCtD
Sitaxentan—EDNRA—Signaling by GPCR—CALCA—thyroid cancer	0.000293	0.00251	CbGpPWpGaD
Sitaxentan—Oedema peripheral—Doxorubicin—thyroid cancer	0.000293	0.000465	CcSEcCtD
Sitaxentan—CYP2C9—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.000292	0.00251	CbGpPWpGaD
Sitaxentan—Angiopathy—Epirubicin—thyroid cancer	0.000292	0.000463	CcSEcCtD
Sitaxentan—Urethral disorder—Doxorubicin—thyroid cancer	0.000292	0.000462	CcSEcCtD
Sitaxentan—Immune system disorder—Epirubicin—thyroid cancer	0.000291	0.00046	CcSEcCtD
Sitaxentan—Mediastinal disorder—Epirubicin—thyroid cancer	0.00029	0.000459	CcSEcCtD
Sitaxentan—Visual impairment—Doxorubicin—thyroid cancer	0.000287	0.000455	CcSEcCtD
Sitaxentan—Alopecia—Epirubicin—thyroid cancer	0.000284	0.00045	CcSEcCtD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—thyroid cancer	0.000283	0.00243	CbGpPWpGaD
Sitaxentan—Mental disorder—Epirubicin—thyroid cancer	0.000282	0.000447	CcSEcCtD
Sitaxentan—Malnutrition—Epirubicin—thyroid cancer	0.00028	0.000444	CcSEcCtD
Sitaxentan—Eye disorder—Doxorubicin—thyroid cancer	0.000278	0.000441	CcSEcCtD
Sitaxentan—Tinnitus—Doxorubicin—thyroid cancer	0.000278	0.00044	CcSEcCtD
Sitaxentan—Cardiac disorder—Doxorubicin—thyroid cancer	0.000276	0.000438	CcSEcCtD
Sitaxentan—Flushing—Doxorubicin—thyroid cancer	0.000276	0.000438	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—PTCH1—thyroid cancer	0.000275	0.00236	CbGpPWpGaD
Sitaxentan—Tension—Epirubicin—thyroid cancer	0.000275	0.000435	CcSEcCtD
Sitaxentan—Nervousness—Epirubicin—thyroid cancer	0.000272	0.000431	CcSEcCtD
Sitaxentan—CYP3A4—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000272	0.00233	CbGpPWpGaD
Sitaxentan—Angiopathy—Doxorubicin—thyroid cancer	0.00027	0.000428	CcSEcCtD
Sitaxentan—Muscle spasms—Epirubicin—thyroid cancer	0.000269	0.000427	CcSEcCtD
Sitaxentan—Immune system disorder—Doxorubicin—thyroid cancer	0.000269	0.000426	CcSEcCtD
Sitaxentan—Mediastinal disorder—Doxorubicin—thyroid cancer	0.000268	0.000425	CcSEcCtD
Sitaxentan—EDNRA—Signaling by GPCR—CDK1—thyroid cancer	0.000265	0.00228	CbGpPWpGaD
Sitaxentan—Alopecia—Doxorubicin—thyroid cancer	0.000263	0.000417	CcSEcCtD
Sitaxentan—Mental disorder—Doxorubicin—thyroid cancer	0.000261	0.000413	CcSEcCtD
Sitaxentan—Ill-defined disorder—Epirubicin—thyroid cancer	0.00026	0.000412	CcSEcCtD
Sitaxentan—Malnutrition—Doxorubicin—thyroid cancer	0.000259	0.000411	CcSEcCtD
Sitaxentan—Anaemia—Epirubicin—thyroid cancer	0.000259	0.00041	CcSEcCtD
Sitaxentan—Agitation—Epirubicin—thyroid cancer	0.000257	0.000408	CcSEcCtD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000255	0.00219	CbGpPWpGaD
Sitaxentan—Tension—Doxorubicin—thyroid cancer	0.000254	0.000403	CcSEcCtD
Sitaxentan—Malaise—Epirubicin—thyroid cancer	0.000253	0.0004	CcSEcCtD
Sitaxentan—Nervousness—Doxorubicin—thyroid cancer	0.000252	0.000399	CcSEcCtD
Sitaxentan—Vertigo—Epirubicin—thyroid cancer	0.000252	0.000399	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—SST—thyroid cancer	0.000251	0.00216	CbGpPWpGaD
Sitaxentan—Leukopenia—Epirubicin—thyroid cancer	0.000251	0.000397	CcSEcCtD
Sitaxentan—Muscle spasms—Doxorubicin—thyroid cancer	0.000249	0.000395	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—CALCA—thyroid cancer	0.000242	0.00208	CbGpPWpGaD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—thyroid cancer	0.000241	0.00206	CbGpPWpGaD
Sitaxentan—Ill-defined disorder—Doxorubicin—thyroid cancer	0.00024	0.000381	CcSEcCtD
Sitaxentan—CYP2C19—Biological oxidations—RXRA—thyroid cancer	0.00024	0.00206	CbGpPWpGaD
Sitaxentan—Anaemia—Doxorubicin—thyroid cancer	0.000239	0.00038	CcSEcCtD
Sitaxentan—Chest pain—Epirubicin—thyroid cancer	0.000238	0.000378	CcSEcCtD
Sitaxentan—Agitation—Doxorubicin—thyroid cancer	0.000238	0.000377	CcSEcCtD
Sitaxentan—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.000237	0.000375	CcSEcCtD
Sitaxentan—Discomfort—Epirubicin—thyroid cancer	0.000236	0.000373	CcSEcCtD
Sitaxentan—Malaise—Doxorubicin—thyroid cancer	0.000234	0.00037	CcSEcCtD
Sitaxentan—Dry mouth—Epirubicin—thyroid cancer	0.000233	0.00037	CcSEcCtD
Sitaxentan—Vertigo—Doxorubicin—thyroid cancer	0.000233	0.000369	CcSEcCtD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000233	0.002	CbGpPWpGaD
Sitaxentan—Leukopenia—Doxorubicin—thyroid cancer	0.000232	0.000368	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—TSHR—thyroid cancer	0.000231	0.00198	CbGpPWpGaD
Sitaxentan—Confusional state—Epirubicin—thyroid cancer	0.00023	0.000365	CcSEcCtD
Sitaxentan—Oedema—Epirubicin—thyroid cancer	0.000229	0.000362	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—PRKAR1A—thyroid cancer	0.000228	0.00195	CbGpPWpGaD
Sitaxentan—Infection—Epirubicin—thyroid cancer	0.000227	0.00036	CcSEcCtD
Sitaxentan—Nervous system disorder—Epirubicin—thyroid cancer	0.000224	0.000355	CcSEcCtD
Sitaxentan—Thrombocytopenia—Epirubicin—thyroid cancer	0.000224	0.000355	CcSEcCtD
Sitaxentan—Tachycardia—Epirubicin—thyroid cancer	0.000223	0.000353	CcSEcCtD
Sitaxentan—Skin disorder—Epirubicin—thyroid cancer	0.000222	0.000352	CcSEcCtD
Sitaxentan—Chest pain—Doxorubicin—thyroid cancer	0.000221	0.00035	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—CDK1—thyroid cancer	0.000219	0.00188	CbGpPWpGaD
Sitaxentan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000219	0.000347	CcSEcCtD
Sitaxentan—CYP2C9—Biological oxidations—RXRA—thyroid cancer	0.000219	0.00188	CbGpPWpGaD
Sitaxentan—Discomfort—Doxorubicin—thyroid cancer	0.000218	0.000345	CcSEcCtD
Sitaxentan—Anorexia—Epirubicin—thyroid cancer	0.000218	0.000345	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—MEN1—thyroid cancer	0.000218	0.00187	CbGpPWpGaD
Sitaxentan—Dry mouth—Doxorubicin—thyroid cancer	0.000216	0.000342	CcSEcCtD
Sitaxentan—Hypotension—Epirubicin—thyroid cancer	0.000214	0.000338	CcSEcCtD
Sitaxentan—Confusional state—Doxorubicin—thyroid cancer	0.000213	0.000338	CcSEcCtD
Sitaxentan—Oedema—Doxorubicin—thyroid cancer	0.000211	0.000335	CcSEcCtD
Sitaxentan—Infection—Doxorubicin—thyroid cancer	0.00021	0.000333	CcSEcCtD
Sitaxentan—Nervous system disorder—Doxorubicin—thyroid cancer	0.000207	0.000329	CcSEcCtD
Sitaxentan—Thrombocytopenia—Doxorubicin—thyroid cancer	0.000207	0.000328	CcSEcCtD
Sitaxentan—Insomnia—Epirubicin—thyroid cancer	0.000207	0.000328	CcSEcCtD
Sitaxentan—Tachycardia—Doxorubicin—thyroid cancer	0.000206	0.000327	CcSEcCtD
Sitaxentan—Skin disorder—Doxorubicin—thyroid cancer	0.000205	0.000326	CcSEcCtD
Sitaxentan—Somnolence—Epirubicin—thyroid cancer	0.000203	0.000322	CcSEcCtD
Sitaxentan—Anorexia—Doxorubicin—thyroid cancer	0.000202	0.000319	CcSEcCtD
Sitaxentan—Dyspepsia—Epirubicin—thyroid cancer	0.000201	0.000319	CcSEcCtD
Sitaxentan—Decreased appetite—Epirubicin—thyroid cancer	0.000199	0.000315	CcSEcCtD
Sitaxentan—Hypotension—Doxorubicin—thyroid cancer	0.000198	0.000313	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000197	0.000313	CcSEcCtD
Sitaxentan—Fatigue—Epirubicin—thyroid cancer	0.000197	0.000312	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—PTCH1—thyroid cancer	0.000197	0.00169	CbGpPWpGaD
Sitaxentan—Pain—Epirubicin—thyroid cancer	0.000195	0.00031	CcSEcCtD
Sitaxentan—Constipation—Epirubicin—thyroid cancer	0.000195	0.00031	CcSEcCtD
Sitaxentan—Insomnia—Doxorubicin—thyroid cancer	0.000191	0.000303	CcSEcCtD
Sitaxentan—Feeling abnormal—Epirubicin—thyroid cancer	0.000188	0.000298	CcSEcCtD
Sitaxentan—Somnolence—Doxorubicin—thyroid cancer	0.000188	0.000298	CcSEcCtD
Sitaxentan—Dyspepsia—Doxorubicin—thyroid cancer	0.000186	0.000295	CcSEcCtD
Sitaxentan—Decreased appetite—Doxorubicin—thyroid cancer	0.000184	0.000291	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000183	0.000289	CcSEcCtD
Sitaxentan—Fatigue—Doxorubicin—thyroid cancer	0.000182	0.000289	CcSEcCtD
Sitaxentan—Urticaria—Epirubicin—thyroid cancer	0.000182	0.000288	CcSEcCtD
Sitaxentan—Pain—Doxorubicin—thyroid cancer	0.000181	0.000287	CcSEcCtD
Sitaxentan—Constipation—Doxorubicin—thyroid cancer	0.000181	0.000287	CcSEcCtD
Sitaxentan—Body temperature increased—Epirubicin—thyroid cancer	0.000181	0.000286	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—SST—thyroid cancer	0.00018	0.00154	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—MINPP1—thyroid cancer	0.000176	0.00151	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—NRG1—thyroid cancer	0.000176	0.00151	CbGpPWpGaD
Sitaxentan—Feeling abnormal—Doxorubicin—thyroid cancer	0.000174	0.000276	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—CALCA—thyroid cancer	0.000173	0.00149	CbGpPWpGaD
Sitaxentan—Hypersensitivity—Epirubicin—thyroid cancer	0.000168	0.000267	CcSEcCtD
Sitaxentan—Urticaria—Doxorubicin—thyroid cancer	0.000168	0.000266	CcSEcCtD
Sitaxentan—Body temperature increased—Doxorubicin—thyroid cancer	0.000167	0.000265	CcSEcCtD
Sitaxentan—Asthenia—Epirubicin—thyroid cancer	0.000164	0.00026	CcSEcCtD
Sitaxentan—CYP2C9—Metabolism—MINPP1—thyroid cancer	0.000161	0.00138	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—TERT—thyroid cancer	0.000158	0.00135	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CDK1—thyroid cancer	0.000157	0.00134	CbGpPWpGaD
Sitaxentan—Diarrhoea—Epirubicin—thyroid cancer	0.000156	0.000248	CcSEcCtD
Sitaxentan—Hypersensitivity—Doxorubicin—thyroid cancer	0.000156	0.000247	CcSEcCtD
Sitaxentan—Asthenia—Doxorubicin—thyroid cancer	0.000152	0.00024	CcSEcCtD
Sitaxentan—Dizziness—Epirubicin—thyroid cancer	0.000151	0.00024	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—HIF1A—thyroid cancer	0.000151	0.00129	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—NDUFA13—thyroid cancer	0.00015	0.00129	CbGpPWpGaD
Sitaxentan—Vomiting—Epirubicin—thyroid cancer	0.000145	0.00023	CcSEcCtD
Sitaxentan—Diarrhoea—Doxorubicin—thyroid cancer	0.000145	0.000229	CcSEcCtD
Sitaxentan—CYP3A4—Biological oxidations—RXRA—thyroid cancer	0.000144	0.00124	CbGpPWpGaD
Sitaxentan—Rash—Epirubicin—thyroid cancer	0.000144	0.000228	CcSEcCtD
Sitaxentan—Dermatitis—Epirubicin—thyroid cancer	0.000144	0.000228	CcSEcCtD
Sitaxentan—Headache—Epirubicin—thyroid cancer	0.000143	0.000227	CcSEcCtD
Sitaxentan—CYP2C19—Metabolism—CHST14—thyroid cancer	0.000141	0.00121	CbGpPWpGaD
Sitaxentan—Dizziness—Doxorubicin—thyroid cancer	0.00014	0.000222	CcSEcCtD
Sitaxentan—CYP2C9—Metabolism—NDUFA13—thyroid cancer	0.000137	0.00117	CbGpPWpGaD
Sitaxentan—Nausea—Epirubicin—thyroid cancer	0.000136	0.000215	CcSEcCtD
Sitaxentan—Vomiting—Doxorubicin—thyroid cancer	0.000134	0.000213	CcSEcCtD
Sitaxentan—Rash—Doxorubicin—thyroid cancer	0.000133	0.000211	CcSEcCtD
Sitaxentan—Dermatitis—Doxorubicin—thyroid cancer	0.000133	0.000211	CcSEcCtD
Sitaxentan—EDNRB—Signaling by GPCR—NRAS—thyroid cancer	0.000133	0.00114	CbGpPWpGaD
Sitaxentan—Headache—Doxorubicin—thyroid cancer	0.000132	0.00021	CcSEcCtD
Sitaxentan—CYP2C9—Metabolism—CHST14—thyroid cancer	0.000129	0.0011	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—NRG1—thyroid cancer	0.000126	0.00108	CbGpPWpGaD
Sitaxentan—Nausea—Doxorubicin—thyroid cancer	0.000126	0.000199	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—BRAF—thyroid cancer	0.000125	0.00107	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—KRAS—thyroid cancer	0.000114	0.000982	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—HPGD—thyroid cancer	0.000114	0.000975	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—TERT—thyroid cancer	0.000113	0.000969	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—HIF1A—thyroid cancer	0.000108	0.000927	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—MINPP1—thyroid cancer	0.000106	0.00091	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—HPGD—thyroid cancer	0.000104	0.000889	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—HRAS—thyroid cancer	9.73e-05	0.000834	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—NRAS—thyroid cancer	9.52e-05	0.000816	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—AKT1—thyroid cancer	9.46e-05	0.000811	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	9.22e-05	0.000791	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CCND1—thyroid cancer	9.13e-05	0.000782	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—NDUFA13—thyroid cancer	9.02e-05	0.000773	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—BRAF—thyroid cancer	8.95e-05	0.000767	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—PTEN—thyroid cancer	8.81e-05	0.000755	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—AKT1—thyroid cancer	8.59e-05	0.000737	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—CHST14—thyroid cancer	8.48e-05	0.000727	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	8.41e-05	0.000721	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—KRAS—thyroid cancer	8.19e-05	0.000703	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—NRAS—thyroid cancer	7.86e-05	0.000674	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—HRAS—thyroid cancer	6.97e-05	0.000597	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—HPGD—thyroid cancer	6.84e-05	0.000586	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—AKT1—thyroid cancer	6.77e-05	0.000581	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—KRAS—thyroid cancer	6.76e-05	0.00058	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CCND1—thyroid cancer	6.53e-05	0.00056	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—TPR—thyroid cancer	6.53e-05	0.00056	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PRKAR1A—thyroid cancer	6.42e-05	0.000551	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—PTEN—thyroid cancer	6.3e-05	0.000541	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—AKT1—thyroid cancer	6.15e-05	0.000527	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—TP53—thyroid cancer	6.01e-05	0.000515	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—TPR—thyroid cancer	5.95e-05	0.00051	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PRKAR1A—thyroid cancer	5.86e-05	0.000502	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	5.82e-05	0.000499	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—HRAS—thyroid cancer	5.75e-05	0.000493	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—NRAS—thyroid cancer	5.62e-05	0.000482	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	5.31e-05	0.000455	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—AKT1—thyroid cancer	5.08e-05	0.000435	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—SLC5A5—thyroid cancer	4.89e-05	0.000419	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—KRAS—thyroid cancer	4.84e-05	0.000415	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	4.58e-05	0.000393	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—SLC5A5—thyroid cancer	4.46e-05	0.000382	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—TP53—thyroid cancer	4.3e-05	0.000369	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	4.18e-05	0.000358	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—HRAS—thyroid cancer	4.11e-05	0.000353	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—RXRA—thyroid cancer	4.11e-05	0.000352	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	3.99e-05	0.000342	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—TPR—thyroid cancer	3.93e-05	0.000337	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	3.86e-05	0.000331	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—RXRA—thyroid cancer	3.74e-05	0.000321	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	3.64e-05	0.000312	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—AKT1—thyroid cancer	3.63e-05	0.000311	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—SLC5A5—thyroid cancer	2.94e-05	0.000252	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PPARG—thyroid cancer	2.59e-05	0.000222	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—RXRA—thyroid cancer	2.47e-05	0.000212	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PPARG—thyroid cancer	2.36e-05	0.000203	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PTGS2—thyroid cancer	2.04e-05	0.000175	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PTGS2—thyroid cancer	1.86e-05	0.000159	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PTEN—thyroid cancer	1.78e-05	0.000153	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PTEN—thyroid cancer	1.62e-05	0.000139	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PPARG—thyroid cancer	1.56e-05	0.000134	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PTGS2—thyroid cancer	1.23e-05	0.000105	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PTEN—thyroid cancer	1.07e-05	9.17e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—AKT1—thyroid cancer	1.03e-05	8.79e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—AKT1—thyroid cancer	9.35e-06	8.01e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—AKT1—thyroid cancer	6.17e-06	5.29e-05	CbGpPWpGaD
